PF-06281355
Biochem/physiol Actions
PF-06281355 (PF-1355) is an orally available, selective and potent mechanism based inhibitor of the myeloperoxidase (MPO) that reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevated circulating cytokines. PF-06281355 suppresses albuminuria and chronic renal dysfunction in model of anti-Glomerular Basement Membrane (GBM) disease.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
Sold for research purposes under agreement from Pfizer Inc.
Other Notes
This compound was developed by Pfizer for Nitric Oxide & Cell Stress research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.
Packaging
5, 25 mg in glass bottle
| Colour | white to beige |
|---|---|
| Quality Level | 100 |
| Manufacturer | SIGMA-ALDRICH |
| Storage Temp. | room temp |
| Solubility | DMSO: 10 mg/mL, clear (warmed) |
| Form | powder |
| Assay | ≥98% (HPLC) |
There are no downloads for this product.
